Zinzino AB (publ) (ZZ-B.ST), the Scandinavian direct-sales health and wellness company, delivered an impressive financial performance in the fourth quarter of 2025. Revenue reached SEK 1,035.3 million, marking a 45% increase compared to SEK 713.5 million in Q4 2024. When adjusted for local currencies, revenue growth climbed even higher to 52%.
The company’s profitability also strengthened significantly. EBITDA rose to SEK 175.2 million, compared to SEK 72.9 million the previous year. This improvement pushed the EBITDA margin to 16.9%, up from 10.2%. The growth was largely driven by higher gross profit margins and operational synergies, particularly following the acquisition of Zurvita.
Net profit for the quarter totaled SEK 123.7 million, with earnings per share (EPS) increasing to SEK 3.41. Strong operational execution also boosted cash flow from operating activities to SEK 271.5 million.
For the full year 2025, Zinzino AB recorded total revenue of SEK 3,337.5 million, representing 51% growth compared to SEK 2,207.8 million in 2024. This remarkable expansion highlights the company’s accelerating global footprint in personalized nutrition and scientific skincare.
EBITDA increased to SEK 443.4 million, up from SEK 250.7 million the previous year, while the EBITDA margin improved to 13.3%. Net profit rose to SEK 324.5 million, and earnings per share reached SEK 9.09.
The company also strengthened its financial position, reporting cash and cash equivalents of SEK 771.0 million at year-end, demonstrating solid liquidity and operational stability.
Following a strong year of growth and profitability, Zinzino’s Board of Directors has proposed a dividend of SEK 6.00 per share for the 2025 financial year. This represents an increase from the previous year’s SEK 4.00 dividend.
The proposed dividend corresponds to a total payout of approximately SEK 217.9 million, subject to approval at the Annual General Meeting scheduled for June 2, 2026. The increased dividend reflects management’s confidence in sustainable growth and long-term shareholder value creation.
Zinzino AB continued its aggressive global expansion strategy throughout 2025. During the fourth quarter, the company acquired a 35% stake in Xion International Group, a move aimed at securing sustainable omega-3 production through algae bioreactors. This investment supports long-term supply stability for the company’s flagship product, BalanceOil.
Additionally, Zinzino acquired the assets of Sanki Global, strengthening its distribution network across North and South America. The company also launched its new Gut Health Test, expanding its portfolio of test-based personalized nutrition solutions.
After the reporting period, Zinzino further enhanced its global presence by acquiring It Works!, increasing distribution power across North America and Europe.
Zinzino AB is a publicly listed global direct-sales company headquartered in Gothenburg, Sweden. The company specializes in test-based, personalized nutrition and scientific skincare, with products available in over 100 markets worldwide.
Over the years, Zinzino has expanded through strategic acquisitions, including It Works!, Zurvita, Truvy, Bodē Pro, Valentus, Enhanzz Global, Xelliss, and Sanki Global. It also co-owns Cleanthi Alpha-Olenic LTD, a Cypriot olive oil producer, and owns HANZZ+HEIDII, a Swiss biotech skincare brand.
With research and production facilities in Norway and a growing international distribution network, Zinzino continues to position itself as a leader in personalized health and wellness solutions.
With 51% annual revenue growth, expanding EBITDA margins, strong cash flow, and a higher dividend proposal, Zinzino AB enters 2026 with solid momentum. The company’s focus on vertical integration, sustainable omega-3 sourcing, and strategic acquisitions suggests continued global expansion.
As demand for personalized nutrition and direct-sales wellness products grows worldwide, Zinzino appears well-positioned to capitalize on emerging health trends and strengthen shareholder returns in the coming years.
Zinzino AB’s Year-End Report 2025 clearly reflects a year of exceptional financial growth, strategic acquisitions, and strengthened profitability. With 51% annual revenue growth, improved EBITDA margins, strong cash flow, and a proposed SEK 6.00 dividend, the company has demonstrated both operational efficiency and shareholder commitment. Backed by global expansion, sustainable omega-3 production initiatives, and increased distribution power across key markets, Zinzino AB appears well-positioned for continued growth in 2026 and beyond. Investors and market analysts will closely watch how the company leverages its expanding global footprint to sustain this strong upward momentum.
Get more information
There are no reviews yet. Be the first one to write one.
